Login / Signup

Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever.

Sinan TrabulusMerve KorkmazEda KayaNurhan Seyahi
Published in: Clinical transplantation (2018)
Canakinumab can be considered as a safe and efficient drug in preventing the FMF attacks in kidney transplant recipients.
Keyphrases
  • early onset
  • emergency department
  • multiple myeloma
  • combination therapy
  • adverse drug
  • replacement therapy
  • smoking cessation